NMRA Options (NMRA20260220C2.5) Price & Quote

Symbols

--(--)

Expected P&L on Expiry

Key Stats

0.00DAY`S RANGE0.00

Open

0.00

Prev.Close

0.00

Turnover

Volume

Premium

Extrinsic Value

Open Interest

Intrinsic Value

Pricing Model

Delta

Gamma

Theta

Vega

Rho

Theor Price

About NMRA20260220C2.5

Underlying

Neumora Therapeutics, Inc.

Industry

Pharmaceutical

Introduction

Neumora Therapeutics, Inc., was founded in November 2019 as a Delaware corporation under the name RBNC Therapeutics, Inc. The company changed its name to Neumora Therapeutics, Inc., in October 2021. The company is a clinical-stage biopharmaceutical company that takes a fundamentally different approach to the treatment of brain diseases in response to the global brain disease crisis. The company's rapidly expanding therapeutic pipeline now includes seven clinical and preclinical neuroscience programs targeting a wide range of underserved neuropsychiatric and neurodegenerative diseases with new mechanisms of action. The company's most advanced product candidate, navacaprant (NMRA-140), is a new once-daily oral kappa opioid receptor (KOR) antagonist being developed for the treatment of major depression disorder (MDD), which the company believes has the potential to provide significant advantages over standard of care if approved.